NASDAQ:GLYC

GlycoMimetics - GLYC Stock Forecast, Price & News

$2.25

+0.03 (+1.35%)

(As of 12/7/2022 11:06 AM ET)

Add

Compare

Today's Range: $2.20
▼
$2.25
50-Day Range: $0.55
▼
$2.29
52-Week Range: $0.51
▼
$2.49

Volume: 647 shs
Average Volume: 944,750 shs
Market Capitalization: $117.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

GlycoMimetics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.55
Upright™ Environmental Score
News Sentiment: 0.06
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$143,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.91) to ($0.65) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

585th out of 1,023 stocks

Pharmaceutical Preparations Industry

279th out of 501 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for GlycoMimetics.

3.0

Short Interest

Percentage of Shares Shorted
1.42% of the float of GlycoMimetics has been sold short.
Short Interest Ratio / Days to Cover
GlycoMimetics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in GlycoMimetics has recently increased by 3.55%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
GlycoMimetics does not currently pay a dividend.
Dividend Growth
GlycoMimetics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
GlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for GlycoMimetics is -0.55.

2.8

News and Social Media Coverage

News Sentiment
GlycoMimetics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for GlycoMimetics this week, compared to 1 article on an average week.
Search Interest
18 people have searched for GLYC on MarketBeat in the last 30 days. This is an increase of 260% compared to the previous 30 days.
MarketBeat Follows
11 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GlycoMimetics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $143,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.00% of the stock of GlycoMimetics is held by insiders.
Percentage Held by Institutions
50.65% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for GlycoMimetics are expected to grow in the coming year, from ($0.91) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GlycoMimetics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GlycoMimetics is -2.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GlycoMimetics has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GlycoMimetics (NASDAQ:GLYC) Stock

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Stock News Headlines

December 4, 2022 | americanbankingnews.com

GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com

December 3, 2022 | americanbankingnews.com

GlycoMimetics (NASDAQ:GLYC) Coverage Initiated by Analysts at StockNews.com

December 2, 2022 | finance.yahoo.com

Is GlycoMimetics (GLYC) Outperforming Other Medical Stocks This Year?

December 2, 2022 | finance.yahoo.com

Individual investors account for 44% of GlycoMimetics, Inc.'s (NASDAQ:GLYC) ownership, while hedge funds account for 18%

November 23, 2022 | finance.yahoo.com

After Golden Cross, GlycoMimetics (GLYC)'s Technical Outlook is Bright

November 12, 2022 | finance.yahoo.com

GlycoMimetics Third Quarter 2022 Earnings: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021)

November 10, 2022 | finance.yahoo.com

Insiders at GlycoMimetics, Inc. (NASDAQ:GLYC) recouped some losses this week after buying this year, still down US$49k

November 9, 2022 | finance.yahoo.com

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022

November 8, 2022 | finance.yahoo.com

GlycoMimetics to Participate in Two Upcoming Investor Conferences

November 3, 2022 | finance.yahoo.com

GlycoMimetics Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia Will Be Presented at ASH Annual Meeting

November 2, 2022 | finance.yahoo.com

GlycoMimetics to Report Third Quarter Financial Results on November 9, 2022

October 19, 2022 | globenewswire.com

Acute Myeloid Leukemia Market Size to Surpass US$ 4.31 Billion by 2030 - Growth Plus Reports - GlobeNewswire

October 19, 2022 | benzinga.com

Venous Thromboembolism Pipeline Assessment – Clinical Trials, FDA, EMA, and PMDA Approvals, Emerging Drug - Benzinga

October 13, 2022 | businesswire.com

Vaso-occlusive Crisis-associated with Sickle Cell Disease Drug Pipeline Report 2022 - ResearchAndMarkets.com - Business Wire

October 11, 2022 | businesswire.com

BIO Announces Appointment of Interim CEO - Business Wire

October 4, 2022 | finance.yahoo.com

GlycoMimetics (GLYC) Upgraded to Buy: Here's Why

September 21, 2022 | benzinga.com

12 Health Care Stocks Moving In Tuesday's Intraday Session - bluebird bio (NASDAQ:BLUE), Apexigen (NASDAQ - Benzinga

September 16, 2022 | benzinga.com

Sickle Cell Disease Treatment Global Market to Reach $4 Billion by 2027 - Benzinga

September 14, 2022 | streetinsider.com

Form 425 Maxpro Capital Acquisiti Filed by: Apollomics Inc. - StreetInsider.com

September 9, 2022 | benzinga.com

Sickle Cell Disease Treatment Global Market Report 2022: Increase in the Number of Individuals Suffering - Benzinga

September 8, 2022 | nasdaq.com

GlycoMimetics Says Edwin Rock Joins As Chief Medical Officer - Nasdaq

September 7, 2022 | seekingalpha.com

GlycoMimetics has a new chief medical officer - Seeking Alpha

September 7, 2022 | benzinga.com

GlycoMimetics (GLYC) – GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Invest - Benzinga

September 7, 2022 | finance.yahoo.com

GlycoMimetics to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference

September 6, 2022 | finance.yahoo.com

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Company Calendar

Last Earnings: 11/02/2021
Today: 12/07/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/02/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GLYC
CUSIP: N/A
CIK: 1253689
Web: www.glycomimetics.com
Phone: (240) 243-1201
Fax: 301-738-2137
Employees: 52
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,430,000.00
Net Margins: N/A
Pretax Margin: -57,921.50%
Return on Equity: -85.00%
Return on Assets: -72.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.95
Quick Ratio: 6.95

Sales & Book Value

Annual Sales: $1.16 million
Price / Sales: 101.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.58 per share
Price / Book: 1.42

Miscellaneous

Outstanding Shares: 52,420,000
Free Float: 48,230,000
Market Cap: $117.95 million
Optionable: Optionable
Beta: 2.42

Key Executives

Mr. Harout Semerjian (Age 52)
CEO, Pres & Director
Comp: $481.96k

Mr. Brian M. Hahn (Age 48)
Sr. VP & CFO
Comp: $804.38k

Dr. John L. Magnani (Age 69)
Sr. VP of Research & Chief Scientific Officer
Comp: $803.16k

Ms. Stephanie R. Irish CPA (Age 51)
VP of Accounting

Mr. Christian Dinneen-Long
VP, Corp. Counsel & Corp. Sec.

Mr. Armand Girard (Age 53)
Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel.

Mr. Bruce Johnson
Sr. VP & Chief Commercial Officer

Dr. Edwin Rock M.D.
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GLYC Stock - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings or view top-rated stocks.
How have GLYC shares performed in 2022?: GlycoMimetics' stock was trading at $1.44 on January 1st, 2022. Since then, GLYC shares have increased by 54.2% and is now trading at $2.22.
View the best growth stocks for 2022 here.
When is GlycoMimetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our GLYC earnings forecast.
How were GlycoMimetics' earnings last quarter?: GlycoMimetics, Inc. (NASDAQ:GLYC) announced its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.02. The biotechnology company had revenue of $0.09 million for the quarter. During the same period in the previous year, the firm earned ($0.29) earnings per share.

What other stocks do shareholders of GlycoMimetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX).
What is GlycoMimetics' stock symbol?: GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
Who are GlycoMimetics' major shareholders?: GlycoMimetics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.59%), Renaissance Technologies LLC (1.00%), Two Sigma Investments LP (0.44%) and Two Sigma Advisers LP (0.39%). Insiders that own company stock include Brian M Hahn, Bvf Partners L P/Il, Daniel M Junius, Edwin Rock, John L Magnani and Patricia S Andrews.
View institutional ownership trends.
How do I buy shares of GlycoMimetics?: Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GlycoMimetics' stock price today?: One share of GLYC stock can currently be purchased for approximately $2.22.
How much money does GlycoMimetics make?: GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $116.37 million and generates $1.16 million in revenue each year. The biotechnology company earns $-63,430,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.
How can I contact GlycoMimetics?: GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137.

This page (NASDAQ:GLYC) was last updated on 12/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GlycoMimetics - GLYC Stock Forecast, Price & News

GlycoMimetics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month